|
Age, year
|
0.206 †
|
|
<60
|
37 (57.8%)
|
16 (50%)
|
21 (65.6%)
| |
|
≥ 60
|
27 (42.2%)
|
16 (50%)
|
11 (34.4%)
| |
|
Gender, n (%)
|
1.000 †
|
|
Female
|
10 (15.6%)
|
5 (15.6%)
|
5 (15.6%)
| |
|
Male
|
54 (84.4%)
|
27 (84.4%)
|
27 (84.4%)
| |
|
BMI, n (%)
|
1.000 †
|
|
<18.5
|
4 (6.3%)
|
2 (6.3%)
|
2 (6.3%)
| |
|
≥ 18.5 and <24
|
46 (71.9%)
|
23 (71.9%)
|
23 (71.9%)
| |
|
≥ 24
|
14 (21.9%)
|
7 (21.9%)
|
7 (21.9%)
| |
|
T stage, n (%)
|
0.633 §
|
|
T1
|
3 (4.7%)
|
1 (3.1%)
|
2 (6.3%)
| |
|
T2
|
11 (17.2%)
|
5 (15.6%)
|
6 (18.8%)
| |
|
T3
|
31 (48.4%)
|
18 (56.3%)
|
13 (40.6%)
| |
|
T4
|
19 (29.7%)
|
8 (25%)
|
11 (34.4%)
| |
|
N stage, n (%)
|
0.585 †
|
|
N1
|
18 (28.1%)
|
10 (31.3%)
|
8 (25%)
| |
|
N2
|
24 (37.5%)
|
10 (31.3%)
|
14 (43.8%)
| |
|
N3
|
22 (34.4%)
|
12 (37.5%)
|
10 (31.3%)
| |
|
Metastasis, n (%)
|
19 (29.7%)
|
13 (40.6%)
|
6 (18.8%)
|
0.055 †
|
|
Decreased hemoglobin, n (%)
|
6 (9.4%)
|
4 (12.5%)
|
2 (6.3%)
|
0.668 §
|
|
Normal albumin, n (%)
|
64 (100%)
|
32 (100%)
|
32 (100%)
|
NA
|
|
Increased leucocyte, n (%)
|
10 (15.6%)
|
5 (15.6%)
|
5 (15.6%)
|
1.000 †
|
|
C-reactive protein≥10 mg/L, n (%)
|
31 (48.4%)
|
13 (40.6%)
|
18 (56.3%)
|
0.211 †
|
|
Underlying diseases, n (%)
|
21 (32.8%)
|
10 (31.3%)
|
11 (34.4%)
|
0.790 †
|
